News & Events

SAN DIEGO, Sept. 6, 2022  /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at two upcoming investor conferences. 

Details of the company's participation are as follows:

• H.C. Wainwright 24^th Annual Global Investment Conference
  Details: Dr. Lian will deliver a corporate presentation and Viking management will participate in 1-on-1 meetings
  Conference Dates: September 12-14, 2022
  Presentation Timing: 12:30 – 1:00 p.m. Eastern on Wednesday, September 14, 2022
  Format: Hybrid conference (in person and virtual); webcast available

• Morgan Stanley 20^th Annual Global Healthcare Conference
  Details: Viking management will participate in 1-on-1 meetings
  Conference Dates: September 12-14, 2022
  Format: In-person at Sheraton New York Hotel

A live webcast of the H.C. Wainwright presentation may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts.  Additionally, a replay of the webcast will be available on the Viking website following the conferences. 

Viking Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel first-in-class or best-in-class therapies for the treatment of metabolic and endocrine disorders. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. The company's clinical programs include VK2809, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of lipid and metabolic disorders, which is currently being evaluated in a Phase 2b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. In a Phase 2a trial for the treatment of non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein-cholesterol (LDL-C), patients who received VK2809 demonstrated statistically significant reductions in LDL-C and liver fat content compared with patients who received placebo. The company is also developing VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the potential treatment of various metabolic disorders. VK2735 is currently being evaluated in a Phase 1 clinical trial. In the rare disease space, the company is developing VK0214, a novel, orally available, small molecule selective thyroid hormone receptor beta agonist for the potential treatment of X-linked adrenoleukodystrophy (X-ALD). VK0214 is currently being evaluated in a Phase 1b clinical trial in patients with the adrenomyeloneuropathy (AMN) form of X-ALD. 

For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com. Follow Viking on Twitter @Viking_VKTX.

SOURCE Viking Therapeutics, Inc.